

From: 5.1.2e @demilieutafel.nl
To: 5.1.2e
Cc: restrictiePFAS
Subject: RE: Update on PFAS: Request for Information Issued
Attachments: [image002.png](#)
[image004.png](#)

Dear 5.1.2e

I am currently involved in making an overview of per- and polyfluorinated pharmaceuticals and medical fluorinated polymers. Drug delivery is also within the scope, so I think the product(s) you represent are relevant. We can talk by phone, or exchange questions and answers by e-mail.

My questions to you are:

Which per- and polyfluorinated aerosols do you bring on the market?

Are they seen as part of a medical device or as a medicine, I mean how is the registration (do they fall within the scope of the Aerosol Dispenser Directive?

Can you give an indication of the amounts per treatment or total amounts on the (EU) market?

Do you think that there are viable alternatives?

What would be the consequence of restriction?

I will send my findings to RIVM in January 2021, who will include them in a larger report with other uses such as food contact materials, and others. Please do not hesitate to contact me.

Kind regards,

5.1.2e 5.1.2e

Phone: 5.1.2e

From: 5.1.2e <5.1.2e@mmm.com>
Sent: donderdag 12 november 2020 16:03
To: 5.1.2e @demilieutafel.nl
Subject: FW: Update on PFAS: Request for Information Issued

Dear 5.1.2e I recently approached Exponent to request my company is included in their ongoing request for market information regarding the production and use of PFAS.

See the email trail below – Exponent have directed me to yourself as our products are licenced pharmaceutical aerosols.

Please could you update me on your process and inform me if we may input information to support your analysis?

Best regards

5.1.2e



5.1.2e

M: 5.1.2e | O: 5.1.2e
www.kindevadd.com | 5.1.2e@mmm.com



Updated contact information coming soon!

From: 5.1.2e <5.1.2e@exponent.com>

Sent: 12 November 2020 14:45

To: 5.1.2e <5.1.2e@mmm.com>

Cc: 5.1.2e @emrc.co.uk; 5.1.2e <5.1.2e@mmm.com>; 5.1.2e
 <5.1.2e@mmm.com>

Subject: [EXTERNAL] RE: Update on PFAS: Request for Information Issued

Dear 5.1.2e

Thank you very much for reaching out on this important topic. As you correctly understand, Exponent is working on PFAS projects related to fluorinated gases and food. However, pharmaceutical aerosols are outside the scope of our projects and instead fall into a project concerned with the use of PFAS in medical devices and pharmaceuticals that is being led by De Milieutafel. The contact person there is 5.1.2e
 5.1.2e 5.1.2e @demilieutafel.nl.

We are separately in contact with your colleagues 5.1.2e and 5.1.2e (in copy) in relation to our projects.

I hope that helps and good luck!

Best regards

5.1.2e

5.1.2e

Exponent International Limited

1 Pride Point Drive
 Pride park, Derby DE24 8BX
 Direct 5.1.2e
 Mobile 5.1.2e

Email: 5.1.2e@exponent.com
www.exponent.com

CONFIDENTIALITY NOTICE: This e-mail transmission (and the attachments accompanying it) is intended only for the use of the intended recipient and may contain confidential information belonging to the sender. If you are not the intended recipient, be aware that any disclosure, copying, dissemination, distribution or use of the

contents of this e-mail transmission is strictly prohibited. If you have received this transmission in error, please promptly notify the sender by reply e-mail and then destroy all copies of the transmission.

Registered in England and Wales number: 4234757 VAT Number: GB 785668267

Placing substances or mixtures on the market in Russia?

The deadline for the inventory notification is approaching. Exponent can assist you with all aspects of Eurasia REACH. Please contact: [REDACTED] (5.1.2e) [REDACTED] (5.1.2e) ([exponent.com](https://www.exponent.com)) or [REDACTED] (5.1.2e) [REDACTED] (5.1.2e) ([exponent.com](https://www.exponent.com)) for further information and how we can help you comply with the requirements.

From: [REDACTED] (5.1.2e) <[REDACTED] (5.1.2e) @mmm.com>
Sent: 12 November 2020 11:32
To: [REDACTED] (5.1.2e) <[REDACTED] (5.1.2e) @exponent.com>; [REDACTED] (5.1.2e) @emrc.co.uk
Subject: [EXTERNAL] Update on PFAS: Request for Information Issued

CAUTION: This Email is from an EXTERNAL source. Ensure you trust this email address before replying or clicking on any links or attachments.

Dear [REDACTED] (5.1.2e) we have been made aware overnight of your request for information from manufacturers of medical aerosols containing PFAS.

We are a user of [REDACTED] (5.1.1c) in the manufacture of metered dose inhalers at our facility in Loughborough, UK, with export to world markets.

We would welcome the opportunity to input into your collection of market information, and if this is invited, we would request a 7 day extension to the current deadline in order to facilitate a considered response.

I look forward to hearing from you.

Kind regards

[REDACTED] (5.1.2e)



[REDACTED] (5.1.2e)

M: [REDACTED] (5.1.2e) | O: [REDACTED] (5.1.2e)
www.kindevadd.com | [REDACTED] (5.1.2e) @mmm.com



Updated contact information coming soon!